0 (0%) | 03-28 08:42 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 102.39 | 1-year : | 119.6 |
Resists | First : | 87.66 | Second : | 102.39 |
Pivot price | 84.6 | |||
Supports | First : | 84.06 | Second : | 81.83 |
MAs | MA(5) : | 86.02 | MA(20) : | 84.34 |
MA(100) : | 78.14 | MA(250) : | 70.81 | |
MACD | MACD : | 0.9 | Signal : | 0.7 |
%K %D | K(14,3) : | 65.9 | D(3) : | 65.6 |
RSI | RSI(14): 63.4 | |||
52-week | High : | 87.66 | Low : | 58.75 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DDM ] has closed below upper band by 5.8%. Bollinger Bands are 4.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 87.04 - 87.57 | 87.57 - 88.07 |
Low: | 84.41 - 85.03 | 85.03 - 85.63 |
Close: | 86.04 - 86.96 | 86.96 - 87.84 |
Thu, 28 Mar 2024
Elixirgen Therapeutics' Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki Ko - Neurology Live
Thu, 28 Mar 2024
Santhera's vamorolone NDA receives priority review in China - Pharmaceutical Business Review
Tue, 26 Mar 2024
Why Alzheimer's Drug Approval Delay? $3 Billion in DMD Gene Therapy; ADHD Prevalence - Medpage Today
Tue, 26 Mar 2024
FDA approves oral Duvyzat for Duchenne muscular dystrophy - Medical Xpress
Mon, 25 Mar 2024
FDA Approves Oral Nonsteroidal Treatment, Duvyzat, to Treat DMD - Genetic Engineering & Biotechnology News
Fri, 22 Mar 2024
Duvyzat, a Nonsteroidal Treatment for Duchenne Muscular Dystrophy, Gets FDA Approval - Monthly Prescribing Reference
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |